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Abstract: 
Effective therapy lies in achieving a therapeutic amount of drug to the proper site in the body and 
then maintaining the desired drug concentration for a sufficient time interval to be clinically 
effective for treatment. The blood brain barrier (BBB) hinders most drugs from entering the 
central nervous system (CNS) from the blood stream, leading to the difficulty of delivering 
drugsto the brain via the circulatory system for the treatment, diagnosis and prevention of brain 
diseases. Several brain drug delivery approaches have been developed such as intracerebral and 
intracerebroventricular administration, intranasal delivery, and blood-to-brain delivery as a result 
of transient BBB disruption induced by biological, chemical or physical stimuli such as zonula 
occludens toxin, mannitol, magnetic heating and ultrasound, but these approaches showed 
disadvantages of being dangerous, high cost as well as unsuitability for most brain diseases and 
drugs. The strategy of vector-mediated blood-to-brain delivery which involves improving BBB 
permeability of the drug-carrier conjugate can minimize such side effects; being submicrometre 
objects that behave as a whole unit in terms of their transport and properties, nanomaterials are 
promising carrier vehicles for direct drug transport across the intact BBB as a result of their 
potential to enter the brain capillary endothelial cells by means of normal endocytosis and 
transcytosis due to their small size, as well as their possibility of being functionalized with 
multiple copies of the drug molecule of interest. This review provids a concise discussion of nano 
carriers for drug transport across the intact BBB, various forms of nanomaterials including 
inorganic/solid lipid/polymeric nanoparticles, nanoemulsions, quantum dots, nanogels, liposomes, 
micelles, dendrimers, polymersomes and exosomes are critically evaluated, their mechanisms for 
drug transport across the BBB are reviewed, and the future directions of this area are fully 
discussed. 
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1. Introduction 
The increasing incidence of cerebral diseases as a result of the worldwide aging population  
demands the urgent development of therapeutic, diagnostic, and preventive agents. Whilst brain 
drug development has been limited, owing to the restrictive transport properties of the blood brain 
barrier (BBB), which is a unique regulatory system of brain capillaries that protects the brain 
environment by preventing most molecules in the blood stream from entering the central nervous 
system [1-6].  Thus, unlike other organs in the human body, more than 98% of small molecules 
and nearly 100% of large therapeutic molecules cannot reach brain via the circulatory system [7]. 
One strategy for brain drug delivery is bypassing the BBB using highly invasive methods such as 
intracerebral and intracerebroventricular administration [8-9], or non-invasive methods such as 
intranasal delivery. Another strategy is blood-to-brain delivery via circulatory system as a result of 
transient BBB disruption induced by biological, chemical or physical stimuli such as zonula 
occludens toxin, mannitol, magnetic heating and ultrasound [10-13]. These brain drug delivery 
strategies have not been widely used because they are risky, costly, or unsuitable for less localized 
brain diseases [14]. 
The strategy of blood-to-brain delivery which involves improving BBB permeability of drugs or 
drug-carrier conjugates under normal conditions can minimize the above mentioned side effects. 
One approach is to modify the chemical structure of drugs;  so far only one drug  has been 
successful: the conversion of morphine to heroin [15-16]. By coupling drugs with various brain 
nutrients or growth factors, such nutrients/growth factors-mediated delivery showed another 
promising approach to improve BBB permeability of brain drugs, as specific transporter proteins 
for brain nutrients/growth factors on the membrane of brain capillary endothelial cells can also 
facilitate the transfer of some nutrient/growth factor-drug conjugates by means of transcytosis 
[17-18]. Unfortunately, this approach is also of little value because only a small number of drugs 
can be converted to nutrient/growth factor-drug conjugates. 
Nanomaterials are submicrometre objects that behave as a whole unit in terms of their transport 
and properties; it has been found that nanomaterials can internalize into most cells (including brain 
capillary endothelial cells) by means of normal endocytosis and transcytosis due to “nano effects” 
as a result of their small size [19]. Consider their possibility of being functionalized with multiple 
copies of the drug molecule of interest, widespread drug delivery to the brain via the transvascular 
route through the intact BBB by using nanomaterials as a carrier vehicle which can be dubbed 
‘Molecular Trojan Horse’ is possible [20-23]. Nanomaterials have been widely investigated for 
brain drug delivery; in this review paper we  discuss: various forms of nanomaterials for 
blood-to-brain drug delivery through the intact BBB; the mechanisms of nanomaterials-mediated 
drug transport across the BBB; and the future directions  of this innovative area of research. 
2. Nano carriers for drug transport across BBB 
Depending on the method of uploading, therapeutic, diagnostic or preventive molecules can be 
dissolved, entrapped, adsorbed, encapsulated or covalently attached to nanomaterials, to give nano 
sized drug-carrier conjugates in the forms of nanoparticles, liposomes, micelles, nanogels, 
nanoemulsions, quantum dots, dendrimers, exosomes, and polymersomes. These objects are in the 
nanometer (1-1000nm) size range differing markedly from items made of identical materials in the 
terms of properties and functions. With the minimal diameter of blood capillaries being 6-9 
micrometers, nano sized drug-carrier conjugates hold the capability to reach organs via 
bloodstream. The average size of cells in the human body is 10-20 micrometers; thus, adsorption 
or uptake of the nano sized drug-carrier conjugates by cells is possible, providing an opportunity 
to deliver drugs into cells. With the possibility of being surfacely functionalized with targeting 
ligands, nano carriers  offer the capability of transporting drugs across the BBB. 
2.1 Inorganic nanoparticles 
Nanoparticles from inorganic materials such as silica, carbon, metal or metal oxide are solid nano 
sized particulate objects which have been widely used in imaging techniques [24]. Inorganic 
nanoparticles are of stable size and form mono-disperse suspensions in body fluids; their surfaces 
can be functionalized to facilitate BBB penetration. With high surface area, large pore volume, 
good biocompatibility and ease of functionalization, mesoporous silica nanoparticles have been 
conjugated with poly(ethylene glycol) (PEG) for BBB penetration as a result of their improved 
hydrophilicity, the eliminated aggregation in the blood stream, as well as the minimized clearance 
by the reticuloendothelial system (RES) [25]. The fluorescein-doped magnetic silica nanoparticles 
(FMSNs) incorporating therapeutic molecules have been covalently conjugated with the second 
generation (G2) PAMAM (polyamidoamine) dendrimers through 3-(triethoxysilyl) propyl 
isocyanate (ICP) to yield PFMSNs, followed by the reaction with tresylated MPEG 
(Methoxypolyethylene glycol)-5000 to yield PEGylated PFMSNs. It has been found that 
PEGylated PFMSNs could penetrate the intact BBB through transcytosis of vascular endothelial 
cells, with subsequent diffusion into the cerebral parenchyma and  distribution in the neurons. In 
contrast, non-PEGylated FMSNs were not found to cross the BBB, which showed PEG 
modification on the surface of the silica nanoparticles may offer  an opportunity to cross the 
BBB. 
Just like PEG-modified silica nanoparticles, PEG-modified carbon nanotubes (CNTs) also 
exhibited the capability of crossing the BBB. CNTs have ultrahigh surface area that permits 
efficient loading of multiple molecules alongside the nanotube wall, and the supramolecular 
binding of aromatic molecules such as doxorubicin (DOX) can be easily achieved by p-p stacking 
of those molecules onto the polyaromatic surface of nanotubes. Oxidized multi-walled carbon 
nanotubes (O-MWNTs) uploaded with DOX have been conjugated with PEG and angiopep-2; the 
results of intracellular tracking in vitro and fluorescence imaging in vivo demonstrated that the 
combination of O-MWNTs-PEG and angiopep-2 constituted an ideal dual targeting drug delivery 
system for both BBB and glioma cells [26]. 
For some inorganic nanoparticles, lactoferrin (Lf) conjugation showed better efficiency in BBB 
penetration than PEG modification as a result of Lf-receptor-mediated transcytosis of cerebral 
endothelial cells. It has been found that the PEG coating favors the transfer of the underlying 
Fe3O4 nanoparticles across the intact BBB model, while Lf-conjugated Fe3O4 nanoparticles 
exhibited an enhanced ability to cross the BBB in comparison to the PEG-coated Fe3O4 
nanoparticles [27]. Free cationic serum albumin can enter the brain via an adsorptive-transcytosis 
mechanism; and likewise it has shown that magnetic nanoparticles of MnFe2O4 surfacely coated 
with crosslinked serum albumin demonstrated the capability of BBB permeability without any 
breakdown [28]. Other surface coatings, such as poly(isobutylene-alt-1-tetradecene-maleic 
anhydride) (PMA), also facilitate BBB penetration of iron oxide nanoparticles uploaded with 
therapeutic molecules [29]. 
In addition to chemical modification, physical approaches such as magnetism can also be used for 
the enhancement of BBB penetration of Fe3O4 nanoparticles because of their capacity to be 
magnetized in the presence of a magnetic field. It has been found that superparamagnetic iron 
oxide nanoparticles (SPIONs) composed of magnetite (Fe3O4) and maghemite (γ-Fe2O3) can pass 
through human brain microvascular endothelial cells facilitated by an external magnet, which 
showed the magnetic force-mediated dragging of SPIONs through the BBB may denote a novel 
mechanism for the delivery of drugs to the brain [30]. 
Other inorganic nanoparticles, such as gold nanoparticles (GNPs), have also been investigated for 
drug transport across the intact BBB [31]. Although all research results showed inorganic 
nanoparticles are promising carrier vehicles to deliver drugs into brain, the issues of potential 
toxicity as a result of non-degradability and drug delivery efficiency still need to be addressed 
[32]. 
2.2 Solid lipid nanoparticles 
Solid lipid nanoparticles (SLNs) are nano sized dispersions of biocompatible lipids such as 
triglycerides, fatty acids, or waxes, stabilized by surfactants possessing HLB 
(Hydrophile-Lipophile Balance) values lower than 12 [33-34]. With drugs that can be dissolved or 
dispersed in the hydrophobic core, such nano carriers possess the capability to deliver drugs into 
cells. A drug-loaded SLNs suspension consisted of 0.1% (w/w) camptothecin (the model drug), 
2.0% (w/w) stearic acid, 1.5% (w/w) soybean lecithin and 0.5% (w/w) 
polyoxyethylene-polyoxypropylene copolymer (Poloxamer 188) with the average diameter of 
196.8 nm and the Zeta potential of 269.3 mV exhibited higher drug concentration in the brain, 
heart and reticuloendothelial cells-containing organs after intravenous injection in comparison to 
free camptothecin, which indicated that it was possible for the SLNs to cross the BBB [35]. SLNs 
made from stearic acid stabilized with pluronic®F68 showed the possibility to effectively deliver 
atazanavir to human brain endothelial cells in vitro [36]; In vivo test in rats also showed that 
riluzole-uploaded SLNs exhibited a higher capability to carry the drug into the brain [37]. 
Surface modification of SLNs with targeting ligands could be an effective strategy for BBB 
delivery.  Docetaxel-loaded SLNs have been prepared from monostearin, vitamin E and soya 
lecithin,  followed by surface modification with stearylamine-betreliesoxybutyric acid (HBA, a 
ketone body and substrate for monocarboxylic acid transporter which is expressed on BBB) 
conjugate, for drug transport across the intact BBB [38]. The surface modification of docetaxel 
loaded SLNs with HBA resulted in enhanced brain uptake of docetaxel compared with 
un-modified docetaxel loaded SLNs and Taxotere®, which showed HBA present on the surface of 
SLNs caused the nanoparticles to be taken up by the monocarboxylic acid transporter as normal 
HBA and improved the brain uptake of docetaxel compared with un-modified SLNs. Similarly, 
Transferrin (Tf)-conjugated, quinine dihydrochloride-uploaded SLNs made from hydrogenated 
soya phosphatidyl choline (HSPC), triolein, distearylphosphatidylethanolamine (DSPE) and 
cholesterol revealed enhanced uptake in brain tissue compared with un-conjugated SLNs [39]; it 
has also been demonstrated that poly(ethylene glycol)-grafted SLNs made from stearate using egg 
phosphatidyl choline and sodium glycocholate as surfactants uploaded with noscapine can 
improve drug accumulation in mice brain tissue [40]. 
Acting as a carrier vehicle for drug delivery, SLNs have shown the advantages of good 
biocompatibility, degradability as well as the  capacity to be surfacely functionalized for brain 
targeting, while the issue of easy clearance by the RES as a result of their hydrophobicity needs to 
be addressed. 
2.3 Polymeric nanoparticles 
Polymeric nanoparticles are solid carrier vehicles ranging from 1 to 1,000 nm in diameter made 
from natural or synthetic polymers. According to the drug loading methods, therapeutic 
molecules-uploaded polymeric nanoparticles can form nanospheres (drugs are uploaded 
throughout or just onto the surface of the polymeric matrix) or nanocapsules (drugs are surrounded 
by a polymeric shell) which are thermodynamically stable [41]. As a result of the diversity of 
polymers, polymeric nanoparticles can be designed to achieve desired properties such as 
controlled and/or sustained drug release profile, as well as allowing drug release at the targeted 
site over a period of time [42]. For this reason, a variety of polymers have been investigated to 
form nanoparticles for brain drug delivery. β-cyclodextrin, which is composed of cyclic 
oligosaccharides with seven glucose unites that form a hydrophobic central cavity with the 
capacity to host therapeutic molecules, has been quarternized for the preparation of a series of 
quaternary ammonium β-cyclodextrin (QA-CD) nanoparticles. Uploaded with doxorubicin (DOX), 
QA-CD nanoparticles showed permeability across the in vitro BBB by means of endocytosis [43]. 
DOX-uploaded nanoparticles of β-cyclodextrin crosslinked with β-amino ester also showed 
biocompatibility and permeability in an in vitro BBB model without impairing the integrity of the 
barrier [44]. Another synthetic polymer, namely 
poly(MePEG2000cyanoacrylate-co-hexadecylcyanoacrylate) (PEG-PHDCA), demonstrated the 
capacity of their nanoparticles to reach the rat central nervous system after intravenous injection 
[45]. In contrast, polyhexadecylcyanoacrylate (PHDCA) nanoparticles did not penetrate across the 
BBB as a result of less adsorbed apolipoprotein E (ApoE) as well as apolipoprotein B-100 
(ApoB-100) than PEG-PHDCA nanoparticles, which demonstrated that the involvement of 
apolipoproteins played an important role in the brain transport of PEG-PHDCA nanoparticles 
[46]. 
It has been found that some surfactants can enhance the permeability of polymeric nanoparticles 
across the BBB; poly(butylcyanoacrylate) (PBCA) nanoparticles coated with polysorbate 80 have 
been successfully used to transport drugs such as leu-enkephalin dalargin, met-enkephalin 
kyotorphin, rivastigmine and tacrine through the BBB after intravenous injection [47-51]. PBCA 
is a biodegradable and biocompatible polymer; PBCA nanoparticles showed hardly any cytotoxic 
or inflammatory effect at therapeutic concentrations and incubation times, and they did not induce 
nonspecific BBB disruption, but collaborate with plasma apolipoprotein E to facilitate BBB 
crossing [52-53]. 
Poly(lactic-co-glycolic acid) (PLGA) is a polymer with biodegradable and biocompatible nature 
which has been approved by the US FDA for human use. Research has shown that PLGA 
nanoparticle-delivered dopamine reduced  its autoxidation-mediated toxicity in the brain, and 
reversed neurochemical and neurobehavioral deficits in parkinsonian rats [54]. When uploaded 
with a protein drug (tissue inhibitor of matrix metalloproteinases 1, TIMP-1), PLGA nanoparticles 
coated with polysorbate 80 had 11.21%±1.35% penetration, whereas TIMP-1 alone and PLGA 
nanoparticles without polysorbate 80 coating did not cross the endothelial monolayer. Due to no 
significant opening of the BBB caused by un-coated as well as polysorbate 80 coated PLGA 
nanoparticles, polysorbate 80 coating can be used to enhance protein delivery of PLGA 
nanoparticles across the BBB [55]. 
In addition to coating with surfactants, surface functionalization with certain peptides can also 
facilitate BBB penetration of polymeric nanoparticles. Surface-modified PLGA nanoparticles with 
octa-arginine (R8) showed a faster cell uptake compared with the control [56], while the 
fluorescent aminated polystyrene (PS) nanoparticles surfacely functionalized with gH625 (a viral 
fusion peptide derived from the glycoprotein gH of Herpes simplex virus type I) via a covalent 
binding procedure showed a greater uptake by brain endothelial cells than that of the PS 
nanoparticles without the peptide [57]. Modification with a motif of TGNYKALHPHNG (TGN) 
could facilitate BBB penetration of poly(ethylene glycol)-poly(DL-lactide-co-glycolide) 
(PEG-PLGA) nanoparticles, leading to significant higher cellular uptake and in vivo brain 
accumulation [58]. 
As a result of receptor-mediated endocytosis being one of the mechanisms through which nano 
carriers cross the BBB, surface functionalization with targeting ligands represents another 
approach to facilitate BBB penetration of polymeric nanoparticles. Angiopep, a ligand targeting 
the low-density lipoprotein receptor-related protein (LRP) which is over-expressed on the BBB 
and glioma cells, has been conjugated with poly(ethylene glycol)-poly(ε-caprolactone) (PEG-PCL) 
nanoparticles [59]. Compared with non-targeting nanoparticles, a significantly higher amount of 
rhodamine isothiocyanate-labeled targeting nanoparticles were endocytosed by U87 MG cells. Tf 
conjugated nanoparticles of Poly(lactide)-D-α-Tocopheryl polyethylene glycol succinate 
(PLA-TPGS) diblock copolymer showed more efficiency than the bare PLA-TPGS nanoparticles 
in brain delivery [60], while human serum albumin (HSA) nanoparticles covalently coupled with 
Tf or transferrin receptor monoclonal antibodies (OX26 or R17217) also demonstrated the 
capacity to transport drugs across the intact BBB [61]. Lf, a mammalian cationic iron-binding 
glycoprotein belonging to the transferring family, consists of a polypeptide chain of about 690 
amino acids folded into two globular lobes, when conjugated with poly(ethylene 
glycol)-poly(lactide) nanoparticles, significantly facilitates cell uptake of the nanoparticles [62]. 
After intravenous administration, near 3 folds of coumarin-6 were found in the mice brain carried 
by Lf-conjugated nanoparticles compared to that carried by the bare nanoparticles. 
Campared with synthetic polymers, nanoparticles based on natural polymers showed advantages 
of low cost, less toxicity and biodegradability, which provide a potential candidate for brain drug 
delivery. A pluronic-based nano-carrier conjugated with both chitosan and a specific target 
peptide for brain (rabies virus glycoprotein; RVG29) was effective for brain targeting across the 
intact BBB [63]. Chitosan nanospheres conjugated with an anti-mouse transferrin receptor 
monoclonal antibody (TfRMAb) that selectively recognizes the TfR type 1 on the cerebral 
vasculature clearly demonstrated the effectiveness of bringing active peptides to the brain [64]. 
Chitosan nanospheres conjugated with poly(ethylene glycol) (PEG) bearing the OX26 monoclonal 
antibody whose affinity for the transferrin receptor (TfR) may trigger receptor-mediated transport 
across the BBB successfully translocated into the brain tissue after intravenous administration 
[65]. 
Due to hydrophobic molecules exhibiting better permeability in BBB penetration than hydrophilic 
ones, chitosan has been chemically modified to improve hydrophobicity for permeability 
improvement of the nanoparticles in BBB penetration. Trimethylated chitosan (TMC) has been 
synthesized and covalently coupled to the surface of PLGA nanoparticles (PLGA-NP) via a 
carbodiimide-mediated link, the resulted nanoparticles exhibited negligible cytotoxicity and 
enhanced brain uptake following intravenous administration compared with PLGA nanoparticles 
without TMC conjugation [66]. A series of O-substituted alkylglyceryl chitosans with 
systematically varied alkyl chain length and degree of grafting has been prepared through 
synthetic steps that involved the protection of amino moieties via phthaloylation and employed for 
the formulation of aqueous nanoparticulate systems. During in vitro tests using a mouse-brain 
endothelial cell model, the efficient cellular uptake of these nanoparticles has demonstrated and 
identified butylglyceryl chitosan and butylglyceryl N,N,N-trimethyl chitosan as promising 
materials for the formulation of nanoparticles that could act as drug carriers into the brain [67]. 
With the possibility of achieving designed and tailored properties, polymeric nanoparticles have 
significant potential for brain drug delivery across the BBB. Biodegradable polymers exhibit the 
advantage of less accumulation in the body; however, before translation into clinical use, a good 
knowledge of degradation rates as well as catabolites, toxicity, and the possibility of causing 
adverse immunological responses is necessary. 
2.4 Nanogels 
Gels are physically or chemically crosslinked 3-dimensional polymeric networks that swell in 
certain liquids with compatible interfacial energies, and the swollen networks can retain a large 
amount of absorbed liquids [68]. Both aqueous and organic liquids can be supporting media of 
polymeric gels, leading to the formation of hydrogels and organic gels, respectively [69]. With 
good biocompatibility as a result of their relatively high water content, as well as the possibility of 
pharmaceutical molecules to diffuse into (drug loading) and out of (drug release) the swollen 
polymeric networks, hydrogels have been widely investigated for drug delivery [70-71]. 
Nanogels are nanoparticles of hydrogels and offer the prospect of drug transport across the intact 
BBB. It has been reported that nanogels with surface charge exhibited better internalization 
property on cell membrane than neutral ones; Gil and Lowe synthesized polysaccharide-based 
nanogels containing poly(β-amino ester) and β-cyclodextrin for transporting doxorubicin and 
insulin across the BBB, such cationic nanogels enhanced the permeability of insulin across the in 
vitro BBB model by 20% [72].  
It is known that lipophilic molecules are easier to penetrate the BBB than hydrophilic ones; so 
surface functionalization of nanogels has been introduced to accelerate encapsulated drug 
transport across the BBB. Azadia and co-workers prepared nanogels loaded with methotrexate 
(MTX) via an ionic gelation process using chitosan and sodium tripolyphosphate (TPP) as raw 
materials, the surfaces of the MTX-loaded nanogels were modified with polysorbate 80 to 
improve brain drug delivery [73]. The cumulative in vitro release profiles indicated non-Fickian 
diffusion kinetic, apparently governed by both diffusion of the drug out of the nanogels and 
swelling/disintegration of the polymeric networks for both surfactant coated and uncoated 
nanogels. After intravenous administration, remarkably higher brain concentrations of 
methotrexate were achieved with the nanogel formulations in comparison to the free drug, but 
there were no significant differences between the surface-coated and uncoated nanogels [74]. 
Two proteins, connexin 43 (Cx43) and brain-specific anion transporter 1 (BSAT1), which are 
promising targeted antigens for drug delivery to gliomas, have been respectively conjugated with 
the cisplatin-loaded nanogels prepared from aqueous solutions of poly(ethylene glycol) 
(PEG)-block-poly(methyl methylacrylate) (PMAA) and CaCl2 using 1,2-ethylenediamine and 
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) as crosslinkers, for the 
treatment of intracranial gliomas [75]. The median survival of rats treated with targeted nanogels 
conjugated with specific mAbs against extracellular loops of Cx43 and BSAT1 were 27 and 26.6 
days longer than that in control group, respectively, which suggested the effectiveness of the 
ligands in promoting BBB-penetrating efficiency of the nanogels. Conjugation of insulin and Tf 
with the nanogels of crosslinked poly(ethylene glycol) and poly(ethylenimine) for the delivery of 
oligonucleotide in brain also showed similar results [76]. Being hydrophilic carriers, nanogels are 
favorable in uploading aqueously soluble drugs as well as proteins and nuclear acids, while it is 
unsuitable for hydrophobic drugs. 
2.5 Micelles 
Micelles are made from amphiphilic block copolymers which aggregate in aqueous solutions to 
form stable spheroidal nano structures with a hydrophobic core and hydrophilic surface [77]. As a 
result of the possibility of solubilizing poorly water-soluble, lipophilic compounds in the 
hydrophobic core region through hydrophobic interaction and/or hydrogen bonding for easy 
administration, as well as the capacity to conjugate with certain targeting ligands, micelles are 
promising delivery vehicles for brain drugs. 
A polymeric surfactant, poly(oxyethylene)-poly(oxypropylene) block copolymer (pluronic), has 
been used for the preparation of micelles [78]. Fluorescein isotbiocyanate (FITC) was solubilized 
in the micelles; it has been found that conjugation of FITC-containing micelles with insulin vector 
resulted in increase of FITC penetration in all tissues including the brain. By conjugating the 
micelles with antibodies to the antigen of brain glial cells (α2-glycoprotein), the specific targeting 
of the solubilized FITC was observed in the brain, which showed that vector-containing pluronic 
micelles provide an effective transport of solubilized neuroleptics across the  BBB. 
TAT (49-57, YGRKKRRQRRR) peptide, the protein transduction domain from the transcriptional 
activator TAT protein of the human immunodeficiency virus type-1, has been anchored with 
cholesterol-terminated poly(ethylene glycol) (PEG) with a molecular weight of about 3 kDa 
(PEG-b-Chol), to form a functionalized TAT-PEG-b-Chol amphiphilic block copolymer [79]. 
FITC-loaded polymeric micelles self-assembled from the block copolymer exhibited the 
possibility of crossing the BBB and entering the brain, which showed that the TAT-conjugated 
micelles may in the future be used to deliver antibiotics across the BBB for the treatment of brain 
infections. 
Several amphiphilic block copolymers have been synthesized and used for preparation of micelles; 
and several targeting ligands have been conjugated for the improved crossing of the intact BBB, 
such as poly(ethylene glycol)-block-poly-(L-glutamic acid),  poly(ethylene 
glycol)-block-poly(D,L-lactide acid), cholesterol conjugated polyoxyethylene sorbitol oleate 
(CPSO), cyclic Arg-Gly-Asp (cRGD) ligand, and angiopep (a family of 19 amino acid peptides 
derived from the Kunitz domain) [80-82]. However, the efficiency of micelles delivering drugs 
across the intact BBB still needs further investigation. 
2.6 Liposomes 
Liposomes are nano sized vesicles with an aqueous inner core enclosed by unilamellar or 
multilamellar phospholipid bilayers. The common constituents that form part of phospholipid 
bilayer are naturally produced sphingomyelin, phosphatidylcholine, or glycerophospholipids [84]. 
With good biocompatibility, as well as the possibility of uploading drugs in the aqueous core, 
liposomes have been widely investigated for systemic delivery of therapeutics [85]. 
Several issues have impeded the drug delivery application of conventional liposomes; one is 
opsonization and rapid clearance by macrophages of the mononuclear phagocytic system (MPS) 
organs. By using surface coatings such as poly(ethylene glycol) (PEGylated liposomes), the 
circulation time of liposomes in the body can be prolonged [86]. Another is their low drug 
transport rate. By conjugating with targeting ligands, liposomes showed the possibility to transport 
drugs to certain organs including the brain. For example, the lipid bilayer of a 3/7 
cholesterol/dipalmitoylphosphatidylcholine mixture was coated with 
n-alkyldimethylammoniumcyclodextrins which host adamantoylglucose molecules as a result of 
the adamantoyl moieties being included in the cyclodextrin cavities; such liposomes showed a 
5-fold improved ability to enter the BBB endothelial cells compared with the non-coated samples 
[87]. The glucose moiety of the ligand provided special affinity of the liposome with BBB 
endothelial cells, leading to  an improvement of the transport rate. Doxorubincin liposomes 
conjugated with both folate and transferrin (Tf) also showed effectiveness in penetrating the BBB 
and targeting brain tumors [88]. 
Cationization of the conjugated ligands is another method to improve BBB transport rate of 
liposomes. Liposomes made from cholest-5-en-3-ol-(3β)-[2-[[4-[(carboxymethyl) 
dithio]-1-iminobutyl]amino]ethyl] carbamate (CHETA5), a cholesterol derivative with a disulfide 
bond inside, were neutral or negatively charged at physiological pH. When they touched brain 
capillary endothelial cells with the help of a brain-targeting ligand, Lf, they were changed into 
cationic liposomes [89]. Such liposomes showed an improved performance in the uptake 
efficiency and cytotoxicity of the primary brain capillary endothelial cells. Liposomes conjugated 
with cationized bovine serum albumin showed similar results compared with sterically stabilized 
(PEGylated) liposomes without protein as well as liposomes conjugated with native bovine serum 
albumin [90]. 
Other issues limiting the brain delivery of liposomes are the poor stability, as well as the difficulty 
of binding ligands to the surface as a result of the small number of available surface groups and 
steric hindrance. 
2.7 Dendrimers 
Dendrimers are monodisperse symmetric macromolecules that comprise a series of branching 
units around an inner core [91]. With many reactive groups on the surface, the number of arms 
and surface groups exponentially increase with each generation [92].  
Being composed of repetitive units of branched molecules, dendrimers form a 3-dimensional 
spheroidal shape and radially crowded layers. As a result, the core is loosely packed in 
comparison to the periphery and is suitable for the entrapment of drugs. In addition, the presence 
of numerous surface groups allows for high drug payload and/or multifunctionality. Combined 
with their nanometer size range, dendrimers are attractive carrier vehicles for drug delivery [93]. 
The surface groups of dendrimers can be conjugated with ligands for transport across the BBB, as 
well as for targeting specific cells such as tumor cells. Thus, dendrimers are promising tailorable 
delivery systems for improved delivery of drugs to the brain. Li and co-workers have synthesized 
the fourth generation poly(amidoamine) (PAMAM) dendrimers with transferrin (Tf) conjugated 
on the exterior and tamoxifen (TAM) encapsulated in the interior [94]. It has been found that each 
dendrimer is a pH-sensitive drug carrier that can encapsulate 29 TAM molecules in the interior, 
and bond 7 doxorubicine (DOX) molecules, over 30 PEG1000 and PEG2000 chains and one Tf 
group on the periphery. The drug-dendrimer conjugate showed a fast drug release profile at weak 
acidic condition and a stable state at physiological environment, as well as a good BBB 
transportation ability with the transporting ratio of 6.06% in 3h. Angiopep, a ligand targeting to 
the low-density lipoprotein receptor-related protein-1 (LRP1), has been conjugated with PAMAM 
dendrimers for effective brain-targeting gene delivery [95]. Such a nano carrier was observed to 
be internalized by brain capillary endothelial cells (BCECs) through a clathrin- and 
caveolae-mediated energy-depending endocytosis, also partly through marcopinocytosis. 
Compared with the dendrimers without modification, angiopep-modified dendrimers showed 
higher efficiency in crossing the intact BBB, and more in vivo accumulation in the brain. Other 
research results also showed the capacity of targeting ligand conjugated dendrimers to cross the 
intact BBB [96-97]. 
Before translation of dendrimers into brain drug delivery use, it is necessary to address their 
biocompatibility issue. For example, PAMAM dendrimers have been shown to be haemolytic and 
cytotoxic [98]. Some research results also showed that biotinylated PAMAM dendrimers may 
prove to be more toxic compared to PAMAM dendrimers alone [99]. 
2.8 Nanoemulsions 
Nanoemulsions are heterogenous dispersions of oil-in-water (O/W) or water-in-oil (W/O) 
formulations stabilized with surface-active agents, where diameter of the inner phase is reduced to 
nanometer length scale [100]. The possibility of surface  functionalization for targeting, as well 
as the ability to solubilize hydrophobic (O/W nanoemulsions) or hydrophilic (W/O nanoemulsions) 
drugs, could facilitate the uptake of nanoemulsions along with its encapsulated drugs through 
receptor-mediated endocytosis of cells, which makes nanoemulsions are promising carrier 
vehicles for drug transport across the BBB. 
For biocompatibility purpose, nanoemulsions are usually made from edible oils such as flaxseed 
oil, pine-nut oil, hemp oil, fish oil as well as safflower oil and wheat-germ oil, biocompatible 
surfactants such as egg phosphatidylcholine which is one of the components of cell membrane 
lipids, deoxycholic acid, stearylamine, dioleoyltrimethylammoniumpropane (DOTAP), and water. 
The versatility of nanoemulsions is based on the different types of oils and surface modifiers that 
can be used [101]. The nanoemulsions of pine-nut oil with the oil droplet size of approximately 
200 nm in diameter have been formulated for the delivery of paclitaxel (PTX) and C6-ceramide 
(CER) to the brain [102]; it has been found that the O/W nanoemulsions can improve the cytotoxic 
effect in brain tumor cells. As a result, pine-nut oil with high gamma linolenic acid content was 
expected to rapidly penetrate across the BBB and thus, incorporating paclitaxel in pine-nut 
oil-containing nanoemulsions was hypothesized to increase the drug availability in the brain. 
In another study, O/W nanoemulsions containing saquinavir (SQV), an anti-HIV protease inhibitor, 
have been developed by dissolving SQV in different types of edible oils rich in essential 
polyunsaturated fatty acids (PUFA), followed by emulsifying in water containing surfactants 
Lipoid®-80 and deoxycholic acid [103]. When administered orally and intravenously to male 
Balb/c mice, the resultant flax-seed oil nanoemulsions with an average oil droplet size of 100-200 
nm showed enhanced rate and extent of SQV absorption in the brain in contrast to aqueous 
suspension formulation. 
Compared with other nano carriers, the advantages of nanoemulsions for overcoming the BBB are  
the ability to utilize safe oils, as well as possessing several beneficial biological properties as a 
result of essential omega-3 and omega-6 fatty acid in the oils. However, the thermodynamic 
instability is a shortcoming of nanoemulsions and requires further considersation. 
2.9 Exosomes 
Exosomes  are a kind of nano sized membranous vesicle secreted by a number of cell types and 
can be isolated from conditioned cell media or bodily fluids such as urine and plasma [104]. Once 
released from a cell, exosomes can fuse with membrane of another cell, transferring exosomal 
molecules from one cell to another [105]. This property provides exosomes with the chance to 
transport drugs into cells. The uptake mechanism of exosomes is clathrin mediated endocytosis 
followed by back fusion with the limiting membrane of the endosomes, allowing for the  
possibility of exosomes to cross the intact BBB [106]. 
Being secreted by living cells in the body, exosomes are natural delivery vehicles with advantages 
of non-toxicity, minimal immune responses, and better stability in the circulatory system in 
contrast to established formulations [107]. Alvarez-Erviti and co-workers used self-derived 
dendritic cells for exosome production; targeting peptides for muscle and brain were used to 
functionalize the exosomes [108]. Uploading exogenous siRNA onto the exosomes by 
electroporation, it has been found that the exosomes delivered siRNA specifically to neurons, 
microglia, and oligodendrocytes in the brain, resulting in a specific gene knockdown after 
intravenous injection. Yang and co-workers isolated four types of exosomes from brain cell 
culture media for drug delivery, and found that exosome-delivered anticancer drugs crossed the 
intact BBB and entered into the brain [109]. 
Proof of concept has been  gained for exosome-based brain drug delivery systems; several issues 
should be addressed before clinical evaluation such as the choice of exosome donor cells, drug 
loading procedures, as well as the targeting peptides. 
2.10 Quantum dots 
Quantum dots are a class of colloidal semi-conductor nano crystals composed of a metalloid 
crystalline core (such as cadmium selenium) and an intermediate unreactive metallic shell (such as 
zinc sulfide) that shields the core [110]. Such an inorganic nano material has high brightness, 
long-term photo-stability, and size-tunable narrow emission spectra, which makes it a 
revolutionary imaging technology for diagnostic purposes (fluorescent probes) [111]. With the 
possibility of being co-incorporated with a variety of diagnostic and therapeutic molecules for 
targeted therapy of CNS disorders as a result of their high surface area, quantum dots also showed 
the potential as a carrier vehicle for blood-to-brain drug delivery. 
The outer coating of quantum dots can be chemically functionalized with bioactive molecules that 
promote aqueous solubility and desired bioactivity, enable targeting of specific molecules, as well 
as carrying therapeutic molecules [112]. Captopril-conjugated CdSe/ZnS-core/shell-typed 
quantum dots (QDs-cap) have been synthesized by the hot soap method with tri-n-octyl phosphine 
oxide (TOPO) followed by the replacement of TOPO with captopril by a thiolexchange reaction. 
It has been found that intraperitoneally administered QDs-cap in mice were delivered through 
systemic blood circulation into the brain as well as into the liver, spleen and kidney, which 
showed the possibility of such quantum dots to penetrate the BBB [113]. 
It is widely known that the Tf receptor is a kind of specific BBB transporter that allows selected 
biomolecules to move across the BBB; lysine-coated CdSe/CdS/ZnS quantum dots have been 
synthesized followed by conjugation with Tf. It has been found that the migration rate of such 
Tf-conjugated QDs crossing the in vitro BBB model was concentration- and time-dependent after 
a systemic administration, which demonstrated a receptor-mediated transport mechanism [114]. 
TAT, a cell membrane translocation peptide, has been successfully used to internalize 
nanoparticles [115]. Research has shown that TAT-conjugated CdS:Mn/ZnS quantum dots can 
label the brain tissue within a few minutes after being intra-arterially delivered to a rat brain 
without manipulating the BBB; such TAT-conjugated quantum dots migrated beyond the 
endothelial cell line and reached the brain parenchyma [116-117]. Because the same quantum dots 
without TAT did not label the brain tissue, TAT peptide was necessary for the quantum dots to 
overcome the BBB. 
2.11 Polymersomes 
Polymersomes are a nanometer-sized vesicular system with a bi-layered membrane which is 
composed of amphiphilic block copolymers [118]. Such tiny hollow spheres can be formed from 
synthetic amphiphilic block copolymers using organic solvent, organic solvent/water systems, or 
aqueous media. Usually, amphiphilic block copolymers with a hydrophilic fraction of 35±10% 
will aggregate to form polymersomes [119-120]. 
Polymersomes enclose an aqueous solution in the core, which is useful for encapsulation and 
delivery of hydrophilic drugs, while the membrane of copolymer aggregates bi-layer can be 
loaded with small hydrophobic drugs [121-122]. Polymersomes are similar to liposome in 
structure; the main difference is that the external bi-layer is composed of amphiphilic copolymers 
with a molecular weight of up to 100 kDa, while the building block of liposome is in most cases 
naturally occurring phospholipid with a molecular weight below 1 kDa [123-124]. With regard to 
the use of building blocks with high molecular weight, the membrane of polymersomes is thicker 
than that of liposome, providing a higher durable physical barrier that protects the enclosed drugs 
[125]. When used for drug delivery, the more robust and therefore less leaky membrane of 
polymersome can improve circulation time and prevent uncontrolled release of drugs [126-127]. 
Being a nano carrier vehicle, polymersomes have been functionalized with certain receptors for 
brain drug delivery across the BBB. Pang and co-workers synthesized biodegradable 
poly(ethyleneglycol)-poly(ε-caprolactone) (PEG-PCL) and used the block copolymer to prepare 
polymersomes (PO) by a nano precipitation method [128]. To facilitate brain targeting, the 
polymersomes were functionalized with Tf to form a conjugate Tf-PO. Using coumarin-6 as a 
model drug, fluorescent microscopy of brain coronal sections revealed more Tf-PO than PO 
accumulated in the brain after injection, and it has been evidenced that Tf-PO uptake by 
beta-End.3 cells occurred mainly through a clathrin-mediated, energy-dependent endocytosis and 
that both the Golgi apparatus and lysosomes were involved in intracellular transport of Tf-PO. 
Lf also belongs to the transferring family and exists on the BBB involved in Lf transport across 
the BBB, which provides another chance for brain targeting of polymersomes. Gao and 
co-workers prepared polymersomes of poly(butadiene-b-ethylene oxide) (PBD-PEO), 
poly(ethylene glycol-b-lactic acid) (PEG-PLA) and maleimide-PEG-PLA (Mal-PEG-PLA) (the 
weight ratio of PBD-PEO:PEG-PLA:MAL-PEG-PLA was 7:2:1) using the film rehydration 
method [129], both Lf and Tf were used to functionalized the polymersomes (Lf-PO and Tf-PO) 
for brain targeting. It was found that cell uptake of both Lf-PO and Tf-PO were time-, 
temperature-, and concentration-dependent, which suggested a process of active endocytosis. Tf 
was more effective than Lf in facilitating cell uptake of the nano carriers, and Lf-PO was more 
easily identified and eliminated by cells of the mononuclear phagocytic system (MPS). 
Polymersomes prepared by self-assembly of methoxy-PEG-PLGA and maleimide-PEG-PLGA 
which were synthesized by the ring opening polymerization of D,L-lactide and glycolide showed 
similar results when conjugated with Tf [130]. 
Several polymersomes have been investigated for brain drug delivery; various receptors expressed 
on the BBB such as low-density lipoprotein receptor, insulin receptor, insulin-like growth factor 
receptor, diphtheria toxin receptor and nicotinic acetylcholine receptor provided many chances for 
the functionalization of polymersomes to mediate their penetration of the BBB. Poly(carboxyl 
ethylene glycol-g-glutamate)-co-poly(distearin-g-glutamate) (CPEGGM-PDSGM) copolymer, 
poly(methyl ethylene glycol-g-glutamate)-copoly(distearin-g-glutamate) (mPEGGM-PDSGM) 
copolymer, des-octanoyl ghrelin-poly(ethylene glycol-gglutamate)-co-poly(distearin-g-glutamate) 
(des-octanoyl ghrelin-PEGGM-PDSGM) copolymer, poly(tert-butyl hydrazinecarboxylate 
ethylene glycol-g-glutamate)-co-poly(distearin-g-glutamate) (BPEGGM-PDSGM) copolymer, as 
well as folate-poly(ethylene glycol-g-glutamate)-co-poly(distearin-g-glutamate) 
(folate-PEGGM-PDSGM) copolymer have been prepared, different types of polymersomes based 
on such copolymers have been developed and conjugated with both des-octanoyl ghrelin and 
folate as a penetrating-targeting carrier for an enhanced drug transport through the BBB and 
glioma cells targeting [131]. It has been found that with bi-functional ligands on the surface of 
polymersomes, the BBB transport was greatly enhanced and the inhibition of glioma growth was 
significantly improved via a synergistic effect of two different endocytosis mechanisms by 
des-octanoyl ghrelin and folate. 
Although several research results showed the possibility of receptor functionalization-mediated 
BBB penetration of polymersomes, the efficiency of drug transport was not ideal. In addition, the 
application of protein and antibody receptors is restricted by their instability and immunogenicity. 
3. Mechanisms of nanomaterials transporting drugs across the BBB 
Based on the biological characteristics of the BBB, the mechanisms of nano carriers transporting 
drugs across the BBB can be classified as follows: (1) transient BBB opening induced by the 
stimulus derived from “nano effects” or “nano toxicity” of the nano carriers, or the stimulus of 
surfactants coated on the surface of nano carriers, which results in diffusion of the drugs or 
drug-carrier conjugates into the brain parenchyma; (2) adsorption of the drug-carrier conjugates 
onto the surface of brain capillary endothelial cells, followed by drug release from the carrier 
vehicles on the surface, which increases drug concentration gradient facilitating diffusion of the 
drugs into the brain parenchyma; (3) transcytosis, endocytosis, and exocytosis of the drug-carrier 
conjugates by brain capillary endothelial cells, which results in direct penetration into the brain 
parenchyma or the cells [132-134]. 
It has been found that some chitosan-derived nanoparticles were capable of opening the tight 
junctions of the BBB [135-136], while high concentrations of some anionic nanoparticles and 
cationic nanoparticles disrupted the BBB even though neutral nanoparticles and low 
concentrations of anionic nanoparticles have no effect on BBB integrity [137]. Sodium 
dodecylsulphate, a surfactant which is regarded as biocompatible, has also been found the 
capability to induce a breach in the blood brain barrier [138]. Transient BBB opening as a result of 
the stimulus derived from nano carriers or surfactants is dangerous as a result of the nano carrier’s 
toxicity, as well as the possibility of other molecules in blood stream diffusing into the brain 
parenchyma at the same time. 
Adsorption of the drug-carrier conjugates onto the surface of brain capillary endothelial cells 
depends on hydrophilicity, surface charge, and targeting ligands of the nano carrier. A lipophilic 
surface of the nano carrier facilitates the adsorption; and a positive surface charge of the nano 
carrier promotes electrostatic interactions with the negative charges of endothelial surfaces which 
also facilitate the adsorption [139-140]. Targeting ligands such as the apolipoproteins in plasma 
adsorbed on the surface of the nano carrier can target low density lipoprotein receptors on the 
microvessel endothelial cells, which facilitates the adsorption [141]. 
For the fate of drug-carrier conjugates adsorbed on the surface of brain capillary endothelial cells, 
one is desorption followed by re-entering the blood stream. In this case, the uploaded drug can 
release from the carrier vehicle on the surface of BBB during adsorption and then diffuse into the 
brain parenchyma through the BBB. Therefore, the possibility of drug penetrating into the brain 
parenchyma will be determined by characteristics of the drug. To promote drug transport across 
the BBB, it is necessary to modify the surface of the nano carriers for the minimization of 
clearance by the fixed macrophages of the mononuclear phagocytic system (MPS) and prolonged 
blood circulation enhancing exposure of the BBB. Improving hydrophilicity and increasing 
surface charge are good methods for nano carriers to mask themselves from the MPS. Another fate 
of the adsorbed drug-carrier conjugates is endocytosis by the cells, sometimes followed by 
exocytosis, leading to penetration of the nano carrier into the cells or brain parenchyma. 
Endocytosis may occur by means of random uptake of soluble plasma molecules together with a 
bulk of plasma by caveolaes on the cells; such a process is independent of any interaction between 
the transported molecules and the caveolar vesicle membrane [142]. Because the brain capillary 
endothelial cells are characterized by few caveolaes while a high density of negatively charged 
and clathrin-coated pits through which drug-carrier conjugates can be be endocytosed, endocytosis 
of drug-carrier conjugates is mainly based on the adsorption of drug-carrier conjugates to the 
clathrin-coated pit membrane [143]. 
Although it is a normal biological function of cells, endocytosis is energy-dependant which does 
not exhibit any preference for nano carriers conjugated with drugs, leading to a low efficiency of 
drug transport across the BBB. Several approaches have been proposed to promote endocytosis of 
nano carriers by brain capillary endothelial cells; one is coating the nano carriers with surfactants 
whose effectiveness has been testified. Three mechanisms have been proposed to explain 
surfactant-coating promoted endocytosis, namely [144-148]: (1) polysorbate 80 or poloxamers 
188-induced adsorption of apolipoproteins A-I and/or E in plasma onto the surface of the nano 
carrier facilitating targeting low density lipoprotein receptors on the cell membrane; (2) 
surfactant-induced fluidity of the cell membrane contacted with the adsorbed drug-carrier 
conjugates facilitating deformation of the cell membrane and promoting endocytosis; and (3) 
surfactant-induced BBB opening. 
Promoting adsorption of drug-carrier conjugates to the brain capillary endothelial cells is another 
approach to prompt endocytosis; seeking help from specific carriers, transport proteins, or 
receptors on the membrane of cells has been employed. The relative high BBB permeability of 
acrylic nanoparticles has been attributed to the apolipoproteins in plasma adsorbed on the surface 
of the nano carrier targeting low density lipoprotein receptors on the microvessel endothelial cells 
by some researchers [149]. Many nano carriers have been surfacely functionalized with a series of 
functional peptides such as Tf and Lf, and both in vitro and in vivo tests have shown their 
effectiveness in promoting BBB penetration of the nano carriers. Because such specific carriers, 
transport proteins, or receptors expressed on the membrane of brain capillary endothelial cells are 
limited, the possibility of achieving a minimal effective drug concentration in the brain 
parenchyma by carrier-, transporter-, as well as receptor-mediated endocytosis of nano carriers is 
worthy of suspicion. For example, from the data available, the percentages of injected drug dose 
found in the brain after targeting with nano carriers was less than 1% [150]. 
4. Perspective 
Brain drug delivery via the circulatory system is limited by the BBB, which hinders therapy, 
diagnosis and prevention of cerebral diseases. Being a non-invasive approach, 
nanomaterials-mediated delivery transporting drugs across the intact BBB has shown the 
advantages of safety, low cost, as well as suitability for almost all drugs in contrast to other 
approaches of brain drug delivery. A variety of nanomaterials have been investigated for drug 
transport across the BBB; both in vitro and in vivo tests have testified the effectiveness of 
nanomaterials-mediated brain drug delivery. However, despite considerable advances that have 
resulted in improved brain drug delivery profiles over other brain delivery approaches, several 
issues have impeded the therapeutic application of nano carriers in brain drug delivery, namely: 
rapid opsonization, the fast and non-specifc clearance from the circulatory system by 
reticulo-endothelial system (RES) cells of nano carriers with hydrophobic/neutral surfaces; the 
metastable nature of some nano carriers; limited drug loading capacity; need to co-formulate with 
surfactants and co-solvents; aggregation or cluster formation in blood flow of neutral or 
hydrophobic nano carriers; and the most importantly, the low efficiency of crossing the intact BBB, 
leading to the difficulty of achieving effective local drug concentration in the brain parenchyma. 
According to the various mechanisms of drug transport across BBB by nano carriers, only 
penetration of drug-carrier conjugates into the brain parenchyma via transcytosis or endocytosis 
exhibit suitability for all types of brain drugs. Therefore, to obtain a pratical delivery platform for 
brain drugs, it is suggested here that the development of a versatile delivery platform should focus 
on their capability as well as efficiency to be transcytosed or endocytosed. 
In addition, the fate of drug carrier vehicles in the brain is a primary consideration. The first 
requirement for drug carrier vehicles is biocompatibility; compared with drug carrier vehicles 
targeting other organs, the accumulation of nano carriers in the brain parenchyma is a particular 
issue to be addressed in addition to toxicity and immunological response. Biodegradable nano 
carriers or nano carriers with the capability to penetrate out of the brain parenchyma across the 
intact BBB after drug release which can be removed by MPS are preferable. Unfourtunately, at 
present it is still unclear what effects of nano carrier’s accumulation in the brain parenchyma will 
be. 
Lastly, to achieve the minimal effective drug concentration in brain parenchyma while the 
maximal safety drug concentration is not exceeded in other organs, the drug transport efficiency 
across the BBB by nano carriers should be elevated. From this viewpoint, it is necessary to 
explore new approaches facilitating endocytosis of nano carriers by the brain capillary endothelial 
cells, although the efficiency of drug accumulation in the brain parenchyma is not only determined 
by crossing BBB, but also by drug uploading and release profile which are relatively easy to be 
engineered. 
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